Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKED: S-ketamine for Postoperative Delirium in Elderly Thoracic Surgery Patients
NCT05242692Phase 1Completed
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Jun 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of esketamine in postoperative delirium (POD) (2 arms), sponsored by Cancer Center of Guangzhou Medical University. Primary endpoint: Incidence of Postoperative Delirium at 4 days. Started Jun 2022; status: completed.
02
Drugs
esketamine
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on NCT05242692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242692.